Ola Elazazy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ola Elazazy has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Soliman Doghish
Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys) Al‐Azhar University Cairo Egypt
7 shared publications - Mahmoud A. Elrebehy
Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt
6 shared publications Reem K. Shahin
Biochemistry Department, Faculty of Pharmacy Badr University in Cairo (BUC) Cairo Egypt
6 shared publicationsAl-Aliaa M. Sallam
Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abassia, Cairo 11566, Egypt
5 shared publicationsHeba M. Midan
Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt
5 shared publicationsMohammed S. Elballal
Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt
5 shared publications
Latest Publications
- 23 June 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (7) , 1601-1630
From In Silico to Clinic: Harnessing Noncoding RNAs for Diabetes Research and Therapy, a Step toward ncRNA Precision
Diabetes mellitus (DM) represents a heterogeneous group of metabolic disorders characterized by chronic hyperglycemia and progressive metabolic dysregulation, arising from distinct but overlapping pathogenic mechanisms. Emerging evidence positions noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long ncRNAs (lncRNAs), circular RNAs (circRNAs), and P-element-induced WImpy testis-interacting RNAs (piRNAs), as central regulators of pancreatic β-cell integrity, insulin signaling, immune modulation, and metabolic homeostasis. This comprehensive review synthesizes current mechanistic and translational insights into ncRNA biogenesis, regulatory networks, and functional roles across diverse DM subtypes, including type 1, type 2, latent autoimmune diabetes in adults, gestational, monogenic, and the recently recognized type 5 diabetes. Through systematic in silico integration of curated databases (e.g., HMDD v4.0 and LncRNADisease) with experimental evidence, we map disease-specific ncRNA signatures and delineate their regulatory axes in β-cell dysfunction, insulin resistance, inflammatory signaling, and diabetic complications. Increasing data support the clinical relevance of distinct circulating and tissue-specific ncRNAs as minimally invasive biomarkers for early detection, subtype stratification, prognosis, and prediction of therapeutic response. Moreover, mechanistic studies highlight ncRNA-mediated pathways as actionable targets for RNA-based therapeutics and precision medicine strategies, particularly in autoimmune-driven β-cell destruction and metabolic insulin resistance. By bridging computational network analyses with molecular and clinical evidence, this review advances an integrated framework for ncRNA-guided diabetes diagnostics and targeted intervention. We further identify critical methodological and validation gaps that must be addressed to accelerate the translation of ncRNA discoveries from bench to bedside, underscoring their transformative potential in reshaping DM management.
- 23 June 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (7) , 1601-1630
From In Silico to Clinic: Harnessing Noncoding RNAs for Diabetes Research and Therapy, a Step toward ncRNA Precision
Diabetes mellitus (DM) represents a heterogeneous group of metabolic disorders characterized by chronic hyperglycemia and progressive metabolic dysregulation, arising from distinct but overlapping pathogenic mechanisms. Emerging evidence positions noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long ncRNAs (lncRNAs), circular RNAs (circRNAs), and P-element-induced WImpy testis-interacting RNAs (piRNAs), as central regulators of pancreatic β-cell integrity, insulin signaling, immune modulation, and metabolic homeostasis. This comprehensive review synthesizes current mechanistic and translational insights into ncRNA biogenesis, regulatory networks, and functional roles across diverse DM subtypes, including type 1, type 2, latent autoimmune diabetes in adults, gestational, monogenic, and the recently recognized type 5 diabetes. Through systematic in silico integration of curated databases (e.g., HMDD v4.0 and LncRNADisease) with experimental evidence, we map disease-specific ncRNA signatures and delineate their regulatory axes in β-cell dysfunction, insulin resistance, inflammatory signaling, and diabetic complications. Increasing data support the clinical relevance of distinct circulating and tissue-specific ncRNAs as minimally invasive biomarkers for early detection, subtype stratification, prognosis, and prediction of therapeutic response. Moreover, mechanistic studies highlight ncRNA-mediated pathways as actionable targets for RNA-based therapeutics and precision medicine strategies, particularly in autoimmune-driven β-cell destruction and metabolic insulin resistance. By bridging computational network analyses with molecular and clinical evidence, this review advances an integrated framework for ncRNA-guided diabetes diagnostics and targeted intervention. We further identify critical methodological and validation gaps that must be addressed to accelerate the translation of ncRNA discoveries from bench to bedside, underscoring their transformative potential in reshaping DM management.
- 6 January 2026
- Published by Wiley in BioFactors
- Vol. 52 (1) , e70061
Delving Into the Multifaceted Role of Exosomal Cargo in Kidney Diseases: Mechanistic Pathways, Diagnostic Potential, and Therapeutic Applications
Exosomes are nanoscale extracellular vesicles (EVs) that have recently garnered significant attention owing to their crucial role in orchestrating cell‐to‐cell communication. Through the transfer of heterogeneous molecular cargo encompassing lipids, proteins, cytokines, growth factors, and RNAs (including mRNAs, lncRNAs, miRNAs, and circRNAs), they modulate a wide spectrum of physiological and pathological processes. Exosomes have been extensively investigated as diagnostic tools, therapeutic agents, as well as innovative platforms for drug delivery in metabolic, oncological, cardiovascular, and neurological disorders. Culminating evidence has demonstrated the pivotal role of exosomes in renal pathophysiology. Depending on their cargo content, exosomes represent potential biomarkers for early disease detection and survival prediction across various renal pathologies. While current therapeutic interventions are largely confined to attenuating disease progression, exosomes hold the potential to promote regeneration in both acute kidney injury and chronic kidney diseases. The current review comprehensively examines the clinical utility of exosomal cargo as diagnostic and prognostic biomarkers as well as therapeutic agents in kidney diseases, highlighting their crosstalk with critical signaling pathways implicated in renal pathophysiology. Addressing the current challenges in exosome isolation and standardization, and the development of advanced exosome engineering technologies are crucial for the transformation from experimental research settings to clinical practice. This should be augmented by preclinical validation and well‐designed clinical trials, ultimately paving the way for a new era of precision medicine.
- 6 January 2026
- Published by Wiley in BioFactors
- Vol. 52 (1) , e70061
Delving Into the Multifaceted Role of Exosomal Cargo in Kidney Diseases: Mechanistic Pathways, Diagnostic Potential, and Therapeutic Applications
Exosomes are nanoscale extracellular vesicles (EVs) that have recently garnered significant attention owing to their crucial role in orchestrating cell‐to‐cell communication. Through the transfer of heterogeneous molecular cargo encompassing lipids, proteins, cytokines, growth factors, and RNAs (including mRNAs, lncRNAs, miRNAs, and circRNAs), they modulate a wide spectrum of physiological and pathological processes. Exosomes have been extensively investigated as diagnostic tools, therapeutic agents, as well as innovative platforms for drug delivery in metabolic, oncological, cardiovascular, and neurological disorders. Culminating evidence has demonstrated the pivotal role of exosomes in renal pathophysiology. Depending on their cargo content, exosomes represent potential biomarkers for early disease detection and survival prediction across various renal pathologies. While current therapeutic interventions are largely confined to attenuating disease progression, exosomes hold the potential to promote regeneration in both acute kidney injury and chronic kidney diseases. The current review comprehensively examines the clinical utility of exosomal cargo as diagnostic and prognostic biomarkers as well as therapeutic agents in kidney diseases, highlighting their crosstalk with critical signaling pathways implicated in renal pathophysiology. Addressing the current challenges in exosome isolation and standardization, and the development of advanced exosome engineering technologies are crucial for the transformation from experimental research settings to clinical practice. This should be augmented by preclinical validation and well‐designed clinical trials, ultimately paving the way for a new era of precision medicine.
- Open Access
- 22 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1275
A Promising Approach to Psoriasis Vulgaris Management with N-Acetylcysteine and Vitamin E: Targeting the Interplay of Inflammatory and Oxidative Stress
Background: Psoriasis is a persistent, inflammatory skin disease with autoimmune characteristics. Beyond the obvious signs of skin lesions, it has negative systemic repercussions that impair the patient’s quality of life. This study aimed to determine the effectiveness of N-acetylcysteine (NAC) alone or in combination with Vitamin E in the treatment of mild to moderate active psoriasis vulgaris. Methods: This study was an open-label, prospective, randomized, controlled interventional clinical trial conducted at Cairo Hospital for Dermatology and Venereology (Al-Haud Al-Marsoud). In total, 45 patients with mild to moderate symptoms were randomly assigned to three groups, with fifteen patients each, as follows: the control group received the standard psoriatic treatment of topical steroids and salicylic acid; the acetylcysteine group received standard psoriatic treatment in addition to NAC 600 mg per day 30 min prior to breakfast for 8 weeks; and the acetylcysteine and Vitamin E group received standard psoriatic treatment in addition to NAC 600 mg per day, in a similar way of dosing like the previous group, and Vitamin E 1000 mg per day. All participants performed a comprehensive assessment including hematological parameters, the Psoriasis Area and Severity Index (PASI), the Dermatology Life Quality Index (DLQI), malondialdehyde (MDA), and interleukin-36 gamma (IL-36γ). Results: The treatment strategy involving the use of NAC alone and in combination with Vitamin E showed significant improvement in the assessed parameters compared to the control group receiving conventional therapy. The acetylcysteine group showed improvements of 41% in PASI and 49.4% in DLQI, a decrease of 34.3% in MDA, and a decrease of 31% in IL-36γ. Similarly, the acetylcysteine and Vitamin E group showed improvements of 52% in PASI and 42% in DLQI, a decrease of 37% in MDA, and a decrease of 35% in IL-36γ. There were no significant differences found between the N-acetylcysteine and N-acetylcysteine and Vitamin E groups. Moreover, significant positive correlations were found between MDA, IL-36γ, and PASI at baseline and after the third follow-up. Conclusions: This study found promising therapeutic benefits in the addition of NAC to the conventional therapy in psoriatic patients with mild to moderate symptoms, as it significantly improved psoriasis disease outcomes and improved the patient’s quality of life. However, the addition of Vitamin E to the NAC regimen did not show additional benefits.
- 22 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1275
Open AccessA Promising Approach to Psoriasis Vulgaris Management with N-Acetylcysteine and Vitamin E: Targeting the Interplay of Inflammatory and Oxidative Stress
Background: Psoriasis is a persistent, inflammatory skin disease with autoimmune characteristics. Beyond the obvious signs of skin lesions, it has negative systemic repercussions that impair the patient’s quality of life. This study aimed to determine the effectiveness of N-acetylcysteine (NAC) alone or in combination with Vitamin E in the treatment of mild to moderate active psoriasis vulgaris. Methods: This study was an open-label, prospective, randomized, controlled interventional clinical trial conducted at Cairo Hospital for Dermatology and Venereology (Al-Haud Al-Marsoud). In total, 45 patients with mild to moderate symptoms were randomly assigned to three groups, with fifteen patients each, as follows: the control group received the standard psoriatic treatment of topical steroids and salicylic acid; the acetylcysteine group received standard psoriatic treatment in addition to NAC 600 mg per day 30 min prior to breakfast for 8 weeks; and the acetylcysteine and Vitamin E group received standard psoriatic treatment in addition to NAC 600 mg per day, in a similar way of dosing like the previous group, and Vitamin E 1000 mg per day. All participants performed a comprehensive assessment including hematological parameters, the Psoriasis Area and Severity Index (PASI), the Dermatology Life Quality Index (DLQI), malondialdehyde (MDA), and interleukin-36 gamma (IL-36γ). Results: The treatment strategy involving the use of NAC alone and in combination with Vitamin E showed significant improvement in the assessed parameters compared to the control group receiving conventional therapy. The acetylcysteine group showed improvements of 41% in PASI and 49.4% in DLQI, a decrease of 34.3% in MDA, and a decrease of 31% in IL-36γ. Similarly, the acetylcysteine and Vitamin E group showed improvements of 52% in PASI and 42% in DLQI, a decrease of 37% in MDA, and a decrease of 35% in IL-36γ. There were no significant differences found between the N-acetylcysteine and N-acetylcysteine and Vitamin E groups. Moreover, significant positive correlations were found between MDA, IL-36γ, and PASI at baseline and after the third follow-up. Conclusions: This study found promising therapeutic benefits in the addition of NAC to the conventional therapy in psoriatic patients with mild to moderate symptoms, as it significantly improved psoriasis disease outcomes and improved the patient’s quality of life. However, the addition of Vitamin E to the NAC regimen did not show additional benefits.
- 4 September 2023
- Published by Elsevier in Life Sciences
- Vol. 331, 122063
MitoQ combats tumor cell progression in Ehrlich ascites carcinoma mice: A crosstalk between mitochondrial oxidative status, mitophagy, and NF-κB signaling
- 4 September 2023
- Published by Elsevier in Life Sciences
- Vol. 331, 122063
MitoQ combats tumor cell progression in Ehrlich ascites carcinoma mice: A crosstalk between mitochondrial oxidative status, mitophagy, and NF-κB signaling
- 12 July 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 248, 154684
miRNAs orchestration of gallbladder cancer – Particular emphasis on diagnosis, progression and drug resistance
- 12 July 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 248, 154684
miRNAs orchestration of gallbladder cancer – Particular emphasis on diagnosis, progression and drug resistance
- 12 June 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 248, 154612
miRNAs orchestration of testicular germ cell tumors – Particular emphasis on diagnosis, progression and drug resistance
- 12 June 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 248, 154612
miRNAs orchestration of testicular germ cell tumors – Particular emphasis on diagnosis, progression and drug resistance
- 10 June 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 248, 154611
The potential role of miRNAs in the pathogenesis of testicular germ cell tumors - A Focus on signaling pathways interplay
- 10 June 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 248, 154611
The potential role of miRNAs in the pathogenesis of testicular germ cell tumors - A Focus on signaling pathways interplay
- 9 May 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 246, 154512
Long non-coding RNAs and rheumatoid arthritis: Pathogenesis and clinical implications
- 9 May 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 246, 154512
Long non-coding RNAs and rheumatoid arthritis: Pathogenesis and clinical implications
- 5 April 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 245, 154440
miRNAs as potential game-changers in bone diseases: Future medicinal and clinical uses
- 5 April 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 245, 154440
miRNAs as potential game-changers in bone diseases: Future medicinal and clinical uses